대한간호학회지 (Journal of Korean Academy of Nursing)

한국간호과학회 (Korean Society of Nursing Science)
권호 표지
DOI QR코드

DOI QR Code

옥살리플라틴 유도 말초신경독성 측정도구의 고찰

Properties of the Measures to Assess Oxaliplatin-induced Peripheral Neuropathy: A Literature Review

  • 추상희 (연세대학교 간호대학.김모임간호학연구소) ;
  • 이윤주 (부산대학교 간호대학) ;
  • 이영주 (연세대학교 대학원) ;
  • Chu, Sang Hui (College of Nursing.Mo-Im Kim Nursing Research Institute, Yonsei University) ;
  • Lee, Yoon Ju (College of Nursing, Pusan National University) ;
  • Lee, Young Joo (Graduate School, Yonsei University) ;
  • Cleeland, Charles S. (Department of Symptom Research, The University of Texas M.D. Anderson Cancer Center)
  • 투고 : 2015.05.07
  • 심사 : 2015.09.16
  • 발행 : 2015.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The purpose of this study is to provide a comprehensive overview of the various measures available for assessment of oxaliplatin-induced peripheral neuropathy (OXLIPN) and to evaluate the measurement properties of each assessment tool. Methods: A systematic review was conducted to identify existing measures for OXLIPN found in the databases of PubMed, Cochrane Library, Embase, RISS and KoreaMed. The quality of the 24 identified tools was evaluated based on their properties of measurement including content validity, internal consistency, criterion validity, construct validity, reproducibility, responsiveness, floor-ceiling effects and interpretability. Results: Ten (41.7%) of the 24 tools were identified as specific measures for assessing OXLIPN and the most popular type of measures were clinical grading systems by clinicians (58.3%) and only 29.2% of measures were identified as patient reported outcomes. The most frequently used tool was National Cancer Institute-Common Toxicity Criteria (NCI-CTC), but the validity of NCI-CTC has not been reported appropriately. Overall, the Neuropathic Pain Symptom Inventory (NPSI) received the best psychometric scores, and the Chemotherapy-induced Peripheral Neuropathy Assessment Tool (CIPNAT) and Functional Assessment of Cancer Therapy/Gynaecologic Oncology Group-neurotoxicity-12 (FACT/GOG-Ntx-12) followed NPSI. Conclusion: To select appropriate measure, evidences should be accumulated through the clinical use of tools. Therefore, practitioner and researchers are urged to report relevant statistics required for the validation of the currently used measures for assessment of OXLIPN.

키워드

참고문헌

  1. Be couarn Y, Agostini C, Trufflandier N, Boulanger V. Oxaliplatin: Available data in non-colorectal gastrointestinal malignancies. Critical Reviews in Oncology/Hematology. 2001;40(3):265-272. http://dx.doi.org/10.1016/S1040-8428(01)00169-X
  2. Otsu S, Hirashima Y, Nishikawa K, Sakashita H, Morinaga R, Watanabe K, et al. Neurological toxicity in metastatic colorectal cancer patients treated with modified FOLFOX6 plus bevacizumab. Japanese Clinical Medicine. 2014;5:19-23. http://dx.doi.org/10.4137/jcm.s15553
  3. Kim GP, Erlichman C. Oxaliplatin in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology. 2007; 3(2):281-294. http://dx.doi.org/10.1517/17425255.3.2.281
  4. Zedan AH, Hansen TF, Fex Svenningsen A, Vilholm OJ. Oxaliplatin-induced neuropathy in colorectal cancer: Many questions with few answers. Clinical Colorectal Cancer. 2014;13(2):73-80. http://dx.doi.org/10.1016/j.clcc.2013.11.004
  5. Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5:116. http://dx.doi.org/10.1186/1471-2407-5-116
  6. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. Journal of Clinical Oncology. 2004;22(23):4753-4761. http://dx.doi.org/10.1200/jco.2004.03.119
  7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology. 2000;18(16):2938-2947. https://doi.org/10.1200/JCO.2000.18.16.2938
  8. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, et al. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clinical Colorectal Cancer. 2012; 11(2):93-100. http://dx.doi.org/10.1016/j.clcc.2011.10.004
  9. Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn KA, Atherton P, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). Journal of Clinical Oncology. 2014;32(10):997-1005. http://dx.doi.org/10.1200/jco.2013.52.0536
  10. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Piatti M, Colombo N, et al. Grading of chemotherapy-induced peripheral neurotoxicity using the total neuropathy scale. Neurology. 2003;61(9):1297-1300. http://dx.doi.org/10.1212/01.WNL.0000092015.03923.19
  11. Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 1998;9(7):739-744. https://doi.org/10.1023/A:1008344507482
  12. Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nursing. 2011;34(4):E10-E20. http://dx.doi.org/10.1097/NCC.0b013e31820251de
  13. Bennett BK, Park SB, Lin CS, Friedlander ML, Kiernan MC, Goldstein D. Impact of oxaliplatin-induced neuropathy: A patient perspective. Supportive Care in Cancer. 2012;20(11):2959-2967. http://dx.doi.org/10.1007/s00520-012-1428-5
  14. Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, et al. Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive Care in Cancer. 2009;17(12):1483-1491. http://dx.doi.org/10.1007/s00520-009-0613-7
  15. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clinical Colorectal Cancer. 2005;5(Suppl 1):S38-S46. http://dx.doi.org/10.3816/CCC.2005.s.006
  16. Sloan JA, Berk L, Roscoe J, Fisch MJ, Shaw EG, Wyatt G, et al. Integrating patient-reported outcomes into cancer symptom management clinical trials supported by the national cancer institutesponsored clinical trials networks. Journal of Clinical Oncology. 2007;25(32):5070-5077. http://dx.doi.org/10.1200/jco.2007.12.7670
  17. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Nature Reviews Neurology. 2010;6(12):657-666. http://dx.doi.org/10.1038/nrneurol.2010.160
  18. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. Journal of Clinical Epidemiology. 2007;60(1):34-42. http://dx.doi.org/10.1016/j.jclinepi.2006.03.012
  19. Windle G, Bennett KM, Noyes J. A methodological review of resilience measurement scales. Health and Quality of Life Outcomes. 2011;9:8. http://dx.doi.org/10.1186/1477-7525-9-8
  20. Larsen CM, Juul-Kristensen B, Lund H, Sogaard K. Measurement properties of existing clinical assessment methods evaluating scapular positioning and function. A systematic review. Physiotherapy Theory and Practice. 2014;30(7):453-482. http://dx.doi.org/10.3109/09593985.2014.899414
  21. Silva PF, Quintino LF, Franco J, Faria CD. Measurement properties and feasibility of clinical tests to assess sit-to-stand/stand-tosit tasks in subjects with neurological disease: A systematic review. Brazilian Journal of Physical Therapy. 2014;18(2):99-110. http://dx.doi.org/10.1590/S1413-35552012005000155
  22. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Investigation. 1990;8(2):147-159. https://doi.org/10.3109/07357909009017560
  23. Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology. 2006;33(1):15-49. http://dx.doi.org/10.1053/j.seminoncol.2005.12.010
  24. Levi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, et al. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer. 1992;69(4):893-900. http://dx.doi.org/10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X
  25. Kautio AL, Haanpaa M, Kautiainen H, Leminen A, Kalso E, Saarto T. Oxaliplatin scale and national cancer institute-common toxicity criteria in the assessment of chemotherapy-induced peripheral neuropathy. Anticancer Research. 2011;31(10):3493-3496.
  26. Smith EM, Beck SL, Cohen J. The total neuropathy score: A tool for measuring chemotherapy-induced peripheral neuropathy. Oncology Nursing Forum. 2008;35(1):96-102. http://dx.doi.org/10.1188/08.onf.96-102
  27. Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: The QLQ-CIPN20. European Journal of Cancer. 2005;41(8): 1135-1139. http://dx.doi.org/10.1016/j.ejca.2005.02.012
  28. Lee EH, Kim CJ, Kim EJ, Chae HJ, Cho SY. Measurement properties of self-report questionnaires published in Korean nursing journals. Journal of Korean Academy of Nursing. 2013;43(1): 50-58. http://dx.doi.org/10.4040/jkan.2013.43.1.50
  29. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. COSMIN checklist manual [Internet]. Amsterdam, NL: COSMIN Group; 2012 [cited 2015 January 17]. Available from: http://www.cosmin.nl/images/upload/files/COSMIN%20checklist%20manual%20v9.pdf.

피인용 문헌

  1. A Platinum Functional Porphyrin Conjugate: An Excellent Cancer Killer for Photodynamic Therapy vol.92, pp.4, 2015, https://doi.org/10.1246/bcsj.20180382
  2. A Systematic Review of Measurement Properties of Spirituality related Assessment Tools Published in Korean Journals vol.28, pp.1, 2015, https://doi.org/10.7739/jkafn.2021.28.1.133